FIGURE 6 from Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts
Year: 2024
Type: other
Abstract: NCATS screening for synergistic drug combinations with TAK-243 in the CU-ACC1 and NCI-H295R cell lines. One hundred and seven drugs were tested in combination with TAK-243. A, Overall result of the screen with drugs listed in ExcessHSA order. The BCL2 inhibitors (S55746, Navitoclax and Venetoclax) and the mTOR inhibitors (Everolimus and Vistusertib) were indicated as red dots. B and C, Independent validation of the NCATS data for the BCL2 and mTOR inhibitors. ACC cell lines were treated with TAK-243 at the specified concentrations for 72 hours with or without Venetoclax (B) and Everolimus (C). Cell viability was assessed by CellTiter-Glo. Error bars represent SD of triplicates; CI values were also plotted.
Authors: Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, Nai-Yun Sun, Fathi Elloumi, Anish Thomas, Nitin Roper, Diana Grace Varghese, Naoko Takebe, Xiaohu Zhang, Michele Ceribelli, David O. Holland, Erin Beck, Zina Itkin, Crystal McKnight, Kelli M. Wilson, Jameson Travers, Carleen Klumpp-Thomas, Craig J. Thomas, Chuong D. Hoang, Jonathan M. Hernandez, Jaydira Del Rivero, Yves Pommier
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392952992